Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 188 clinical trials
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

This phase II trial studies how well venetoclax and acalabrutinib work in treating patients with mantle cell lymphoma that did not respond to previous treatment or has come back. Venetoclax may cause cancer cell death by blocking the mechanism that cancer cells use to stay alive. Acalabrutinib may stop the …

venetoclax
refractory mantle cell lymphoma
remission
cancer
platelet count
  • 0 views
  • 04 Mar, 2021
  • 1 location
Testing the Addition of an Anti-cancer Drug Triapine to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

This phase I trial studies the side effects and best dose of triapine when given together with lutetium Lu 177 dotatate in treating patients with neuroendocrine tumors. Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radioactive drugs, such as lutetium …

  • 0 views
  • 23 Jul, 2021
  • 5 locations
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Soft Tissue or Bone Sarcoma Metastatic to the Lungs

This phase I/II trial studies the side effects of pulmonary suffusion in controlling minimal residual disease in patients with soft tissue or bone sarcoma that has spread to the lungs. Pulmonary suffusion is a minimally invasive delivery of chemotherapeutic agents like cisplatin to lung tissues. Drugs used in chemotherapy, such …

metastasectomy
2 hemoglobin
isolated chemotherapeutic lung perfusion
antineoplastic
sarcoma
  • 0 views
  • 27 Jan, 2021
  • 1 location
Circulating Tumor DNA in Soft Tissue Sarcoma

This research study will collect blood and tumor tissue samples from patients with soft tissue sarcoma to look at circulating tumor deoxyribonucleic acid (DNA). When tumor cells are damaged or die, DNA from the tumor cells are released into the blood stream as the cells break down. This is called …

cancer
soft tissue sarcoma
liposarcoma
tumor cells
leiomyosarcoma
  • 3 views
  • 22 Apr, 2021
  • 1 location
MRD-guided Treatment in NPM1mut AML Patients

Evaluation the safety and efficacy of Pembrolizumab (PEM) when administered in combination with standard Azacitidine (AZA) in nucleophosmin (NPM1) mutated AML patients with molecular relapse defined by the presence of measurable residual disease (MRD).

anthracyclines
cytarabine
residual tumor
cell transplantation
azacitidine
  • 2 views
  • 24 Jan, 2021
  • 17 locations
Decolonization of Gram-negative Multi-resistant Organisms (MDRO) With Donor Microbiota (FMT)

Colonization by Multiple Drug Resistant Organisms (MDROs) during patient hospitalization requires expensive isolation measures and renders the return or transfer to other departments or institutions often impossible. Currently there is no specific treatment available. Patients have to wait for spontaneous clearance which can take months or does not happen at …

  • 0 views
  • 23 Jan, 2021
  • 1 location
Testing the Combination of XL184 (Cabozantinib) Nivolumab and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

This phase II trial studies how well the combination of XL184 (cabozantinib), nivolumab, and ipilimumab work in treating patients with poorly differentiated neuroendocrine tumors (i.e., neuroendocrine tumor that does not look like the normal tissue it arose from). Cabozantinib may stop the growth of tumor cells by blocking some of …

  • 0 views
  • 19 Jul, 2021
  • 34 locations
Blinatumomab Methotrexate Cytarabine and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive or BCR-ABL Positive or Relapsed/Refractory Acute Lymphoblastic Leukemia

This phase II trial studies how well blinatumomab, methotrexate, cytarabine, and ponatinib work in treating patients with Philadelphia chromosome (Ph)-positive, or BCR-ABL positive, or acute lymphoblastic leukemia that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as blinatumomab, may induce changes in body's immune …

leukemia
serum bilirubin level
tyrosine
methotrexate
cancer
  • 29 views
  • 25 Jan, 2021
  • 2 locations
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

This phase I trial studies the side effects and best dose of selinexor in treating younger patients with solid tumors or central nervous system (CNS) tumors that have come back (recurrent) or do not respond to treatment (refractory). Drugs used in chemotherapy, such as selinexor, work in different ways to …

seizure disorder
glomerular filtration rate
tumor markers
malignant glioma
tumor vaccine
  • 47 views
  • 31 May, 2021
  • 14 locations
Talazoparib in Treating Patients With Recurrent Refractory Advanced or Metastatic Cancers and Alterations in the BRCA Genes

This phase II trial studies how well talazoparib works in treating patients with cancers that have returned after a period of improvement, do not respond to treatment, or have spread to other parts of the body, and have alterations in the breast cancer, early onset (BRCA) genes. Talazoparib may cause …

aptt
glomerular filtration rate
hysterectomy
cancer
breast cancer
  • 10 views
  • 15 Jun, 2021
  • 2 locations